United Therapeutics (UTHR) received a Buy rating and a $195.00 price target from H.C. Wainwright analyst Andrew Fein today. The company’s shares closed last Friday at $163.82, close to its 52-week high of $176.31.
According to TipRanks.com, Fein is a 5-star analyst with an average return of 19.0% and a 54.0% success rate. Fein covers the Healthcare sector, focusing on stocks such as DBV Technologies SA – American, Deciphera Pharmaceuticals, and Global Blood Therapeutics.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for United Therapeutics with a $208.17 average price target, a 26.0% upside from current levels. In a report issued on January 19, Oppenheimer also maintained a Buy rating on the stock with a $200.00 price target.
See today’s analyst top recommended stocks >>
The company has a one-year high of $176.31 and a one-year low of $75.58. Currently, United Therapeutics has an average volume of 359.4K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
United Therapeutics Corp. operates as a biotechnology company, which engages in the development and commercialization of products for patients with chronic and life-threatening diseases. It markets and sells commercial therapies to treat pulmonary arterial hypertension and high-risk neuroblastoma. The firm also involves in the research and development of new indications and delivery devices for its product, and for the organ transplantation-related technologies. The company was founded by Martine A. Rothblatt on June 26, 1996 and is headquartered in Silver Spring, MD.